Study of CART-ddBCMA in Relapsed or Refractory Multiple Myeloma IMMAGINE-1

What's the purpose of this trial?

A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Age 18 years or older and has capacity to give informed consent
  • Relapsed or refractory multiple myeloma treated with at least 3 prior regimens of systemic therapy including proteasome inhibitor, immunomodulatory drugs (IMiDs) and anti-CD38 antibody and are refractory to the last line of therapy. For each line, 2 consecutive cycles are required unless the best response after 1 cycle was progressive disease.
    • Note: IMWG criteria defines refractory disease as disease progression on or within 60 days of a therapy Note: Induction treatment with or without hematopoietic stem cell transplant and with or without maintenance is considered a single regimen
  • Documented measurable disease including at least one or more of the following criteria:
    • Serum M-protein ≥1.0 g/dL
    • Urine M-protein ≥200 mg/24 hours
    • Involved serum free light chain ≥10 mg/dL with abnormal κ/λ ratio (i.e., >4:1 or <1:2)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy >12 weeks
  • Adequate organ function defined as:
    • Oxygen (O2) saturation ≥92% on room air
    • Left Ventricular Ejection Fraction (LVEF) ≥45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
    • Absolute neutrophil count (ANC) ≥1.0k/µl, platelet count (PLT) ≥50k/µl, (NOTE: Platelet transfusion not allowed within 14 days; growth factor neupogen not allowed within 7 days, neulasta within 14 days)
    • Creatinine clearance ≥30 mL/min and not on dialysis
    • Aspartate transaminase (AST)/alanine transaminase (ALT) <3 x upper limits of normal (ULN)
    • Total bilirubin <1.5 x ULN (allow 3x ULN for Gilbert's syndrome)
    • Prothrombin time test (PTT), prothrombin time (PT)/international normalized ratio (INR) <1.5 x ULN, unless on a stable dose of anti-coagulant for a thromboembolic event (Patients with any history of thromboembolic stroke; or history or Grade 2 (G2) or greater hemorrhage within 60 days are excluded)
  • Resolution of adverse events (AEs) from any prior systemic anticancer therapy, radiotherapy, or surgery to Grade 1 or baseline (except G2 alopecia and G2 sensory neuropathy)
  • Male and female participants of childbearing potential must agree to use highly effective methods of birth control through 12 months after the dose of study treatment
  • Willing to comply with and able to tolerate study procedures, including consent to participate in separate Long-term Safety Follow-up lasting up to 15 years per FDA guidance
  • Subject's leukapheresis product from non-mobilized cells is received and accepted for cell processing by manufacturing site

Exclusion Criteria:

  • Plasma cell leukemia or history of plasma cell leukemia
  • Treatment with the following therapies as specified below
    • Any prior systemic treatment for multiple myeloma within the 14 days prior to scheduled leukapheresis unless discussed with medical monitor
    • Receiving high-dose (e.g., >10 mg prednisone or equivalent) systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to leukapheresis
    • Prior treatment with any gene therapy or gene-modified cellular immune-therapy
    • Prior B-cell maturation antigen (BCMA) directed therapy
    • Autologous stem cell transplantation within 3 months prior to leukapheresis, or any prior allogeneic stem cell transplantation
  • Patients with solitary plasmacytomas without evidence of other measurable disease
  • History of allergy or hypersensitivity to study drug components. Patients with a history of severe hypersensitivity reaction to dimethyl sulphoxide (DMSO)
  • Contraindication to fludarabine or cyclophosphamide
  • Severe or uncontrolled intercurrent illness or laboratory abnormalities including
    • Active bacterial, viral, or fungal infection requiring systemic treatment (isolated fever may not constitute active infection in and of itself, (e.g., related to disease)
    • Symptomatic congestive heart failure
    • Unstable angina, arrhythmia, or myocardial infarction (MI) within 6 months prior to Screening
    • Significant pulmonary dysfunction
    • Uncontrolled thromboembolic events or recent severe hemorrhage
    • Any history of pulmonary embolism (PE) in the past 12 months or deep vein thrombosis (DVT) within three months of enrollment. Therapeutic dosing of anticoagulants (e.g., warfarin, low molecular weight heparin, Factor Xa inhibitors) is allowed for history of PE/DVT if greater than twelve and three months, respectively, from time of enrollment, should be at a stable maintenance dose.
    • Auto-immune disease requiring immunosuppressive therapy
  • Seropositive for and with evidence of active hepatitis B or C infection at time of Screening, or HIV seropositive
    • Subjects with a history of hepatitis B but have received antiviral therapy and have non-detectable viral DNA for 6 months are eligible
    • Subjects seropositive because of hepatitis B virus vaccine with no signs or active infection are eligible
    • Subjects who had hepatitis C but have received antiviral therapy and show no detectable hepatitis C virus (HCV) viral RNA for 6 months are eligible
  • Active central nervous system (CNS) involvement by malignancy. NOTE: subjects who are asymptomatic, stable, and received prior effective treatment for CNS disease may be eligible after discussion with medical monitor
  • Any sign of active or prior CNS pathology including history of epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or CNS bleed, severe brain injury, dementia, cerebellar disease, Parkinson's disease, organic brain syndrome or psychosis
  • Active malignancy not related to myeloma that has required therapy in the last 3 years or is not in complete remission. Exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy. Other similar malignant conditions may be discussed with and permitted by the medical monitor
  • Females who are pregnant or breastfeeding or females of childbearing potential not using an effective method of birth control
  • Subjects with any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in study (or full access to medical records) as written including follow up, the interpretation of data or place the subject at unacceptable risk

Additional Trial Information

Phase 2

Enrollment: 110 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


University of Arkansas for Medical Sciences (UAMS)

Little Rock, AR

Not Yet Accepting


Moffitt Cancer Center Magnolia Campus

Tampa, FL

Not Yet Accepting


Northside Hospital (Atlanta)

Atlanta, GA

Open and Accepting


University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

Not Yet Accepting


Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine

Baltimore, MD

Not Yet Accepting


Beth Israel Deaconess Medical Center

Boston, MA

Not Yet Accepting

Dana-Farber Cancer Institute

Boston, MA

Not Yet Accepting

Massachusetts General Hospital

Boston, MA

Open and Accepting


Barbara Ann Karmanos Cancer Institute Wayne State University

Detroit, MI

Not Yet Accepting

New Jersey

John Theurer Cancer Center Hackensack Meridian Health

Hackensack, NJ

Not Yet Accepting

North Carolina

Levine Cancer Institute Atrium Health

Charlotte, NC

Not Yet Accepting


Oregon Health and Science University (OHSU) Knight Cancer Institute

Portland, OR

Open and Accepting


MD Anderson Cancer Center The University of Texas

Houston, TX

Not Yet Accepting


Huntsman Cancer Institute University of Utah

Salt Lake City, UT

Open and Accepting


UW Carbone Cancer Center University of Wisconsin Health

Madison, WI

Open and Accepting

Medical College of Wisconsin Froedtert Hospital

Milwaukee, WI

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message